A carregar...
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
Her-2 gene is over expressed in 15-20 percent of all breast cancers. With the advent of Her-2 directed therapies, Her-2 overexpression is no longer considered an adverse prognostic factor. Despite significant improvements in clinical outcomes with use of trastuzumab, women over the age of 65 remain...
Na minha lista:
| Publicado no: | Drugs Aging |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4991772/ https://ncbi.nlm.nih.gov/pubmed/26645293 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40266-015-0326-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|